Global Multiple Myeloma Market to Reach $40.41B by 2033 with Rising Therapies

According to Renub Research Latest Report multiple myeloma market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, registering a CAGR of 7.11% from 2025 to 2033. Growth is fueled by the rising prevalence of multiple myeloma, breakthroughs in targeted therapies and immunotherapies, and expanding healthcare infrastructure. Advances in diagnostic methods and increased patient awareness further accelerate market adoption, offering hope to patients worldwide.

Market Overview

Multiple myeloma is a type of blood cancer affecting plasma cells in the bone marrow. Malignant plasma cells grow uncontrollably, leading to weakened bones, kidney failure, anemia, and a compromised immune system. It predominantly affects older adults and is diagnosed through blood tests, bone marrow biopsies, and imaging scans.

Treatment options include chemotherapy, immunotherapy, targeted therapies, corticosteroids, and stem cell transplantation. Innovations in monoclonal antibodies and CAR-T cell therapies are enhancing patient outcomes, driving global adoption. Increased government funding and pharmaceutical R&D investment are also contributing to the growing availability and effectiveness of treatments.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Key Market Drivers

1. Advancements in Targeted Therapies

Targeted therapies such as proteasome inhibitors and monoclonal antibodies are improving treatment efficacy while minimizing side effects compared to conventional chemotherapy. CAR-T cell therapy and other immunotherapies are becoming increasingly effective in treating multiple myeloma, leading to higher survival rates.

Pharmaceutical companies are investing heavily in research and development of innovative therapies. For example, in December 2024, Merck reported FDA acceptance for the Biologics License Application of clesrovimab (MK-1654), a long-acting monoclonal antibody aimed at protecting infants from RSV, signaling ongoing innovation in monoclonal antibody treatments.

2. Rising Prevalence of Multiple Myeloma

The global incidence of multiple myeloma is increasing, particularly among older adults. Risk factors include genetic susceptibility, exposure to chemicals, and lifestyle changes. In 2021, the highest number of cases were reported in China (47,003) and Germany (32,010). Europe reported the highest age-standardized incidence and prevalence rates, while North America recorded the highest mortality and disability-adjusted life years (DALYs).

The growing prevalence drives demand for effective therapies, prompting governments and healthcare organizations to invest in research, screening, and treatment availability.

3. Increasing Healthcare Spending and Awareness

Rising healthcare budgets in developed and emerging markets support better access to oncology care. Awareness campaigns, screening programs, and reimbursement schemes are improving early detection and treatment adoption. Hospitals and clinics are expanding oncology services, making innovative therapies more accessible, thereby boosting market growth.

Market Challenges

1. High Cost of Therapy

Advanced therapies, including immunotherapies and targeted agents, are expensive, limiting access, especially in developing countries. Bone marrow transplants and maintenance treatments further increase costs, even with reimbursement schemes, making affordability a major challenge.

2. Side Effects and Therapy Resistance

Patients may develop resistance to treatments over time, requiring frequent regimen modifications. Additionally, side effects such as infections, fatigue, and organ damage affect quality of life, driving the need for continuous innovation in therapies.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Drug Type

Chemotherapy: Conventional therapy, often combined with other treatments. Still essential where targeted therapies are unavailable.

Protease Inhibitors: Target cancer cell proteins to inhibit growth.

Monoclonal Antibodies: Precision therapy targeting specific cancer cells.

Others: Corticosteroids, CAR-T cell therapy, and combination therapies.

By Disease Type

Active Multiple Myeloma: Symptomatic stage with bone damage, kidney impairment, and anemia. Treated with chemotherapy, targeted therapies, and stem cell transplantation.

Smoldering Multiple Myeloma: Early, asymptomatic phase. Patients are monitored or enrolled in clinical trials to delay disease progression using immunomodulatory drugs or targeted therapy.

By End User

Hospitals: Provide advanced oncology care, stem cell transplants, and CAR-T cell therapy.

Clinics: Offer outpatient treatments like chemotherapy, targeted therapy, and supportive care, providing convenience and cost-effectiveness.

Others: Research institutes and specialty centers contributing to patient care and clinical trials.

Regional Insights

United States

The U.S. leads the multiple myeloma market due to strong healthcare infrastructure, research investment, and the presence of leading pharmaceutical companies. FDA approvals of innovative therapies, insurance coverage, and government assistance ensure patient access to high-cost treatments.

In March 2024, Johnson & Johnson announced that the FDA Oncologic Drugs Advisory Committee recommended CARVYKTI for adult patients with relapsed/refractory multiple myeloma who had received prior therapies including proteasome inhibitors and IMiDs.

France

France benefits from technological advancements, precision medicine, and universal healthcare programs. Cancer research centers focus on early detection and innovative therapies. In March 2024, Bristol Myers Squibb received European Commission approval for Abecma® (idecabtagene vicleucel) for adult patients with relapsed and refractory multiple myeloma who failed at least two prior treatments.

India

India’s market is growing due to increased awareness, enhanced diagnostics, and healthcare infrastructure improvements. High treatment costs remain a challenge, but government programs and pharma collaborations are expanding access. In March 2025, the Postgraduate Institute of Medical Education and Research (PGI) initiated clinical trials for CAR-T cell therapy in multiple myeloma patients.

Saudi Arabia

Saudi Arabia is investing in oncology centers and expanding healthcare coverage. Rising cancer incidence and international research partnerships are propelling the market. In May 2024, Kite (Gilead) and Arcellx announced a Phase III trial for anitocabtagene autoleucel (anito-cel), a BCMA CAR-T cell therapy for multiple myeloma.

Competitive Landscape

Key global players driving the multiple myeloma market include:

Novartis AG

AbbVie Inc.

Sanofi

Johnson & Johnson

Baxter International Inc.

Pfizer Inc.

Takeda Pharmaceutical Company Ltd

Bristol-Myers Squibb Company

These companies dominate the market through innovative drug development, strategic collaborations, and expansion of immunotherapies, targeted therapies, and CAR-T cell treatments. Their focus on research and clinical trials is transforming multiple myeloma treatment and improving patient survival worldwide.

Future Outlook

The multiple myeloma market is expected to maintain steady growth over the next decade. Rising prevalence, advances in targeted and immunotherapies, and improved diagnostic methods will continue to expand treatment adoption.

Emerging therapies, such as CAR-T cell therapy and next-generation monoclonal antibodies, will redefine treatment paradigms and enhance survival rates. Regional growth in Asia-Pacific and the Middle East is expected to accelerate due to increasing awareness, government support, and healthcare infrastructure development.

Hospitals and specialized oncology clinics will remain crucial in delivering cutting-edge care, while outpatient treatment models and telehealth will improve access and convenience. Collaborations among pharmaceutical companies, research institutes, and government agencies will continue to fuel innovation and broaden the availability of effective therapies worldwide.

Conclusion

The global multiple myeloma market is poised to reach USD 40.41 billion by 2033, driven by increasing disease prevalence, targeted therapies, immunotherapies, and advanced diagnostics. Despite challenges like high therapy costs and resistance issues, innovations and expanded healthcare access are improving patient outcomes.

With hospitals, clinics, and research centers adopting precision medicine, CAR-T therapies, and monoclonal antibodies, multiple myeloma patients worldwide are experiencing improved survival rates and quality of life. As the market evolves, continuous innovation and regional expansion will shape the future of multiple myeloma care, offering hope and transformative treatments to millions of patients globally.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.